[1] Yuan JL, Zhao RX, Ma YJ, Li XD, Zhou XM, Wang XF, Jiang XY, Li SJ. Prevalence/potential risk factors for motoric cognitive risk and its relationship to falls in elderly Chinese people:a cross-sectional study[J]. Eur J Neurol, 2021, 28:2680-2687. [2] Yuan JL, Zhao RX, Li XD, Jiang XY, Wang XF, Zhou XM, Li SJ. Motoric cognitive risk syndrome increases the risk of hospitalization in the elderly[J]. Ji Chu Yi Xue Yu Lin Chuang, 2021, 41:1169-1173.[袁景林, 赵瑞雪, 李晓东, 蒋晓燕, 王笑峰, 周晓梅, 李淑娟. 运动认知风险综合征增加老年人住院风险[J]. 基础医学与临床, 2021, 41:1169-1173.] [3] Basile G, Sardella A. From cognitive to motor impairment and from sarcopenia to cognitive impairment:a bidirectional pathway towards frailty and disability[J]. Aging Clin Exp Res, 2021, 33:469-478. [4] Beauchet O, Sekhon H, Launay CP, Chabot J, Rolland Y, Schott AM, Allali G. Motoric cognitive risk syndrome and mortality:results from the EPIDOS cohort[J]. Eur J Neurol, 2019, 26:794-e56. [5] Bronas UG, Hannan M, Lash JP, Ajilore O, Zhou XJ, Lamar M. Exercise training and cognitive function in kidney disease:protocol for a pilot randomized controlled trial[J]. Nurs Res, 2022, 71:75-82. [6] Chaiben VBO, Silveira TBD, Guedes MH, Fernandes JPA, Ferreira JHF, Beltrão J, Leal GF, Erbano LHO, Bosch NL, Pecoits Filho R, Moraes TP, Baena CP. Cognition and renal function:findings from a Brazilian population[J]. J Bras Nefrol, 2019, 41:200-207. [7] Wang RR, He M, Gui X, Kang Y. A nomogram based on serum cystatin C for predicting acute kidney injury in patients with traumatic brain injury[J]. Ren Fail, 2021, 43:206-215. [8] Cui Z, Cao G, Wang Y, Ma Q, Wang C, Xu Y, Sun H, Ma Y. Effects of cystatin C on cognitive impairment in older Chinese adults[J]. Am J Alzheimers Dis Other Demen, 2020, 35:1533317520965101. [9] Hu WD, Chen J, Mao CJ, Feng P, Yang YP, Luo WF, Liu CF. Elevated cystatin C levels are associated with cognitive impairment and progression of Parkinson disease[J]. Cogn Behav Neurol, 2016, 29:144-149. [10] Silverwood RJ, Richards M, Pierce M, Hardy R, Sattar N, Ferro C, Savage C, Kuh D, Nitsch D; NSHD scientific and data collection teams. Cognitive and kidney function:results from a British birth cohort reaching retirement age[J]. PLoS One, 2014, 9:e86743. [11] Lau WL, Fisher M, Greenia D, Floriolli D, Fletcher E, Singh B, Sajjadi SA, Corrada MM, Whittle C, Kawas C, Paganini-Hill A. Cystatin C, cognition, and brain MRI findings in 90+-year-olds[J]. Neurobiol Aging, 2020, 93:78-84. [12] Verghese J, Annweiler C, Ayers E, Barzilai N, Beauchet O, Bennett DA, Bridenbaugh SA, Buchman AS, Callisaya ML, Camicioli R, Capistrant B, Chatterji S, De Cock AM, Ferrucci L, Giladi N, Guralnik JM, Hausdorff JM, Holtzer R, Kim KW, Kowal P, Kressig RW, Lim JY, Lord S, Meguro K, Montero-Odasso M, Muir-Hunter SW, Noone ML, Rochester L, Srikanth V, Wang C. Motoric cognitive risk syndrome:multicountry prevalence and dementia risk[J]. Neurology, 2014, 83:718-726. [13] Shen S, Zeng X, Xu L, Chen L, Liu Z, Chu J, Yang Y, Wu X, Chen X. Association between motoric cognitive risk syndrome and frailty among older Chinese adults[J]. BMC Geriatr, 2020, 20:110. [14] Zhang L, Feng BL, Wang CY, Zhang Y, Lin P, Zhang YL, He NN, Wang DJ, Jiang LF, Ye HH. Prevalence and factors associated with motoric cognitive risk syndrome in community-dwelling older Chinese:a cross-sectional study[J]. Eur J Neurol, 2020, 27:1137-1145. [15] Ayers E, Verghese J. Motoric cognitive risk syndrome and risk of mortality in older adults[J]. Alzheimers Dement, 2016, 12:556-564. [16] Meiner Z, Ayers E, Bennett DA, Wang C, Verghese J. Risk factors for the progression of motoric cognitive risk syndrome to dementia:retrospective cohort analysis of two populations[J]. Eur J Neurol, 2021, 28:1859-1867. [17] Verghese J, Ayers E, Barzilai N, Bennett DA, Buchman AS, Holtzer R, Katz MJ, Lipton RB, Wang C. Motoric cognitive risk syndrome:multicenter incidence study[J]. Neurology, 2014, 83:2278-2284. [18] Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, Satterfield S, Atkinson H, Windham BG, Kurella-Tamura M. Cystatin C as a marker of cognitive function in elders:findings from the health ABC study[J]. Ann Neurol, 2008, 63:798-802. [19] Gauthier S, Kaur G, Mi W, Tizon B, Levy E. Protective mechanisms by cystatin C in neurodegenerative diseases[J]. Front Biosci (Schol Ed), 2011, 3:541-554. [20] Kaur G, Levy E. Cystatin C in Alzheimer's disease[J]. Front Mol Neurosci, 2012, 5:79. |